Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Science Translational Medicine
|
August 31, 2012
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans
Anran Wang, Smita Chandran, Syed A Shah, et al.
Cell Reports
|
September 6, 2025
Functional divergence of G protein γ subunits drives plant vigor and improvement through the CPK28-PIP1;2 pathway in tomato
Xiao Liang, Anran Wang, Chenxin Yue, et al.
Breast Cancer Research : BCR
|
March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Rebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
The Lancet. Oncology
|
December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset, Ivan Borbath, Mark Karwal, et al.
Nature
|
February 26, 2025
Automated loss of pulse detection on a consumer smartwatch
Kamal Shah, Anran Wang, Yiwen Chen, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Science Translational Medicine
|
August 31, 2012
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans
Anran Wang, Smita Chandran, Syed A Shah, et al.
Cell Reports
|
September 6, 2025
Functional divergence of G protein γ subunits drives plant vigor and improvement through the CPK28-PIP1;2 pathway in tomato
Xiao Liang, Anran Wang, Chenxin Yue, et al.
Breast Cancer Research : BCR
|
March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Rebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
JCO Precision Oncology
|
April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Sherene Loi, Roberto Salgado, Peter Schmid, et al.
The Lancet. Oncology
|
December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset, Ivan Borbath, Mark Karwal, et al.
Nature
|
February 26, 2025
Automated loss of pulse detection on a consumer smartwatch
Kamal Shah, Anran Wang, Yiwen Chen, et al.
Page
of 11